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ABSTRACT
In 2007, a gene homolog of CDO encoded by the gene Gm237 in the DUF164 family
was identified as cysteamine dioxygenase (ADO). ADO is one of the only known thiol
dioxygenases found in mammals. Both ADO and its partner cysteine dioxygenase (CDO) are
non-heme iron dependent enzymes that play a crucial role in the biosynthesis of
taruine/hypotaurine by insertion of a dioxygen molecule. However, ADO has been
overshadowed by CDO as heavy research focus on CDO over the past decade has led to the
elucidation of its structure and possible mechanistic properties. In an effort to further understand
ADO’s mechanism and regulating role in vivo, this work will be focused on the mammalian
hADO and trying to gain further insight on hADO’s structural features via crystallography work.

Investigation of the crystallization parameters for hADO has elucidated several potential
conditions. Detailed work on these crystallization parameters will be presented.
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1

INTRODUCTION

Enzymes are proteins which functions as biological catalysts. Enzymes are produced in all
living organisms and are necessary in almost all metabolic processes to sustain life1Enzyme
properties are versatile and to date enzymes are used in various assets of applications ranging
from the food and beverage industry, starch and fuel production, organic synthesis,
pharmaceutical etc. Due to evolution of modern biotechnology and protein engineering the
possibilities of utilizing enzymes in multiple facets of life have become possible.2 However, all
of these possibilities would not be available if not for the understanding of enzymes at the
molecular and biological levels.
Enzymes are composed of the building blocks called amino acids. There are 20 key amino
acids utilized by the body’s proteins and they are either obtained from food or synthesized by the
body. When amino acids form polypeptides, they can fold to form three-dimensional structures
due to hydrophobic forces and intermolecular interactions between the amino acid residues. The
structure formed is significant to the amino acid sequence allowing the enzyme to have different
folds and reactive chemical nature. Enzymes can bind specific substrates via different enzyme
binding affinities such as the lock and key model. Many enzymes tend to require cofactors such
as metals, flavin, NAD, etc to perform these enzymatic activities. One key class of enzyme that
incorporates metals is called metalloenzymes. Metalloenzymes are all protein associated with a
metal ion to form a coordinative active site for catalytic activity. Some mettalloenzyme classes
fall under heme and non-heme enzymes where heme enzymes are associated with presence of an
iron porphryin which bonds via covalently or non-covalently interactions and non-heme enzymes
which lack presence of a heme.
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Enzymes have been studied since the 1800s and remain to be the focal point of many
research investigations to date. The biological identification of enzymes remained elusive until
the early 1900s when James B. Sumner showed that the enzyme urease was in a fact a protein
and crystallized it..3 Sumner’s crystallization work opened up the doors for new investigative
premises of enzymes as the discovery that proteins can be crystallized allowed for the structure
analysis of enzymes by x-ray crystallography. Structural biology or protein crystallography has
allowed for the study of enzymes at the atomic level and remains to be a key tool for
understanding the structure and function of an enzyme.

1.1

Protein Crystallography
The discovery of X-rays in the late 1800s along with subsequent developments by

William Brag and his son revealed that X-ray diffraction could be used to determine the atomic
structure of atoms.4 Their work proved to be the foundation for X-ray crystallography as years
later, the first protein structure of myoglobin was determined and published. Since then,
macromolecule crystallography has become a practical tool utilized in various fields and
applications because studies at the atomic level of molecules have proved to be of great value in
revealing structure/function relationship; which is important for understanding how enzymes,
nucleic acids, or other macromolecules will interact in a biological system. Crystallography
studies have become of considerable interest to many different fields including academia,
pharmaceutical, biotechnological, chemical industries, etc as a promising tool in protein
engineering, drug design, and various other biological system studies such as understanding
certain diseases. The elaborate information obtained from the 3-dimensonal structure of a
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protein or other biological macromolecule provides potential information on understanding
mechanisms by which enzymes, receptor, hormones, lipids, etc. function in a biological setting. 5
One key application of protein crystallography is utilizing the information obtained from
the crystal structure to understand enzyme function and mechanism. This involves
understanding the chemical reaction taking place between the substrates, cofactors, etc. involved
for the formation of a product and enzyme kinetics. Understanding these aspects along with the
cellular location of the protein allows insight on cellular regulation which can prove to be useful
information for understanding the nature of particular diseases or abnormal malfunctions.
Information from the structure of proteins can also identify mutational consequences which can
affect enzyme function. There are various types of mutations: substitution, deletion, inversion,
etc. causing the enzyme to be improperly folded or lose/gain enzyme function. Thus, mutations
can greatly affect enzyme activity and cause imbalance in cellular regulation leading to diseases.
Structural crystallography relies mainly on the scattering of X-rays by the electrons in the
molecules of the investigated sample. The crystal is exposed to an X-ray beam and exposed at
various orientations resulting in the scattering of X-ray radiation in selected directions.
Scattering is governed by the geometry of the crystal unit cell while the intensity of the
diffractions depends on the grouping of all atoms within the unit cell. This property allows for 3D diffraction gratings unique to the geometry of the protein. Thus, in general the crystal
structure is encoded in the diffracted X-rays and its intensities which is defined by the shape and
symmetry of the cell. The position of each atom in the unit cell influences the intensities of the
reflections. The primary result from the X-ray diffractions is a map of the electron density
within the crystal and after proper refinement the electron density map can be then be processed.
Several programs today such as Mosflm, XDS, and HKL-2000 were developed for processing
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electron density maps. From the electron density map, a structural model can be built, often with
the assistance of the amino acid sequence information (i.e., the primary structure). The clarity of
the electron maps depends on the resolution of the diffraction data. At low resolutions, it is not
possible to accurately locate or distinguish between individual atoms and their identity.
However, with increasing resolution, it becomes possible to identify the stereochemistry of
individual amino acids and peptide groups to give a clear layout of the protein structure.
Macromolecule crystallography has come a long way as today there is establishment of a Protein
Data Base (PDB) as a repository site for all solved crystal structures. As of today, there are at
least 37,914 deposited crystal structures.

1.2

Protein Dynamic Growth
Protein crystallization is a complex process with various parameters that must be taken

into consideration. One key parameter is the nature and the properties of the protein being
crystallized. Proteins tend to be large, complex molecules which can compose of several
subunits. This can cause proteins to have varying molecular and dynamic properties depending
on the protein’s amino acid sequence which can affect protein crystallization. This can include
but is not limited to relatively flexible structures, chemically or physically instable
conformations, unique three-dimensional folds, or charge and size of the protein. For a crystal to
form, it does not depend on the properties of the protein alone. The interactions between protein
molecules and its surrounding solution environment must align properly to from a crystal with
specific geometric arrangement. Surrounding environmental factors such as pH, ionic strength,
temperature, concentration of protein, etc as shown in Figure 1 are all factors that must be taken
into consideration. Even today, it is still not possible to predict the crystallization conditions of a
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protein as change in a single experimental parameter can influence the outcome of a
crystallization experiment.
Crystallization is an intricate process that involves multiple equilibria between different
states of the species being crystallized. There are three stages commonly associated with
crystallization: 1. nucleation 2. crystal growth 3. cessation of growth. Nucleation occurs when
enough molecules associate in three dimensional forms, resulting in a thermodynamically stable
aggregate which provides a suitable platform for crystal growth. Crystal growth and nucleation
occur in supersaturated solutions when the concentrations of the crystallized species exceed
equilibrium solubility. However, the ideal conditions for suitable crystallization conditions are
finite due to many different factors. 6 Therefore, it is important to guide the process toward a
state of reduced solubility by modifying various parameters to ensure that solubility is decreased
at a slow rate with respect to the nature of the species being crystallized in order to ensure that
orderly crystals are formed instead of amorphous precipitate. The ideal approach would be to
begin at the lowest supersaturation and slowly increase saturation due to depletion of solute from
the solution as this allows the nuclei to grow properly and allow formation of define and stable
crystals which will diffract. 7
A wide variety of chemical, physical, and biochemical parameters affect the protein
crystallization process. The purity of the protein being analyzed, the properties of the solution
being used for crystallization (e.g. salts, buffers, pH, temperature), and the various techniques
used for sampling handling are all important factors that must be taken into consideration. Table
1.2 lists some common parameters that are taken into consideration for protein crystallization.
Table 1. Environmental factors for protein crystallography. Adapted from ref 8&10.
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Physical Factors

Chemical

Biochemical

Factors

Factors

Temperature

Precipitant type

Sample purity

Time

Precipitant
concentration

Macromolecular
impurities

Pressure

pH and buffer

Aggregation

Methodology

Ionic strength

Posttranslational
Modifications

Gravity/Sedimentation

Reducing/oxidizing
environment

Sample source

Vibrations/Sounds

Sample
concentration

Chemical
modifications

Magnetic/Electric Fields

Metal ions

Sequence
modifications

Viscosity

Detergents

Sample
symmetry

Equilibration rate

Polyions

Ligands, cofactors,
inhibitors

Volume

Cross-linkers

Sample pI

Surface of crystallization

Reagent source

Purification
methods

Sample handling

Microbial
contamination

With so many parameters to be considered, there is no exact approach to determine the
proper conditions that must be used to crystallize a protein. A few parameters will be briefly
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discussed here, however more explicit reviews on the different parameters are explained in
sources. 8,10
1.2.1 Ligand/Substrate/Cofactors Parameter
It is often possible to increase the stability of a protein via addition of a ligand, substrate,
nucleic acid, cofactor, or small molecule. 11 The ligand or stabilizing molecule can be added
during various stages to the protein whether if it’s during certain protein purification steps,
during the entire purification process, or during the final concentration before crystallization.
The addition of a ligand may help to stabilize the protein and lessened or elimination issues such
as protein denaturation. It is also applicable to soak the ligands into pre-existing crystals to form
and trap key intermediates to help elucidate the enzymatic pathway. It has been shown that
certain proteins when expressed with a ligand of interest can help protein expression and increase
protein solubility. 12,13 Addition of ligand during the various purification steps of protein
purification such as cell-lysis was the key for the success of obtaining pure protein as seen for
the crystallization of a recombinant enzyme (kinase 1) from a baculovirus in insect cells.
If no ligand was present, purification of the enzyme resulted in a mixture of protein,
DNA, and lipids. If the ligand is soluble, the protein-ligand complex can be formed by adding
the ligand to the protein during the final steps of concentration. It has also been noted that
cofactors such as metals can be a key parameter for crystallization conditions. Many enzymes
requires metals such as Fe, Mg, Ni, etc to be biologically active. For this reason, it is reasonably
expected that incorporating metals, particularly divalent metals to metal dependent enzymes
would help with crystal formation. This could be due to the fact that metal ions can stabilize the
protein and the intermolecular interactions in the crystals.14,15
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1.2.2 Precipitants
Protein solubility can be varied by changing the composition of the solution. This can be
by changing solubility-influencing additives such as alcohols, detergents, hydrophilic polymers,
etc. which are commonly referred to as precipitants. Listed in table 2 are common precipitants.
There are four broad categories for protein precipitants: salts, organic solvents, polymers, and
non-volative organic compounds.
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Table 2. Lists of additives that can affect protein solubility. Adapted from ref 8 & 10.

Salts

Ammonium or sodiumn sulfate

Organic Solvent

Polymers

Ethanol

Poly(ethylene)
glycol 1000,
3350, 6000,
20000, etc.

Lithium sulfate

Isopropanol

Jeffamine T

Lithium chloride

1,3- propandediol

Polyamine

Sodium/ammonium/potassium chloride

Acetone

Sodium/ammonium acetate

Butanol

Magnesium/calcium sulfate

Acetonitrile

Cetyltrimethyl ammonium salts

Dimethyl sulfoxide

Calcium chloride

2,5-hexanediol

Sodium formate

Methanol

Ammonium nitrate

1,3-butyrolactone

The ionic strength of the solution can be increased to decrease the solubility of a protein
by a method referred to as “salting out”. As salt concentration increases, water molecules are
monopolized and form bonds with the small salt ions, causing the protein to aggregate. This
interaction could result in the ordered arrangement of proteins to form crystals.16
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Addition of organic solvents also produces similar effects by competing for water. This
is due to the hydrogen bonding capabilities of organic compounds and leads to the aggregation
and increase elastic forces between protein molecules. The mechanisms of polymers to facilitate
protein crystallization are still not yet clearly understand, however it has been observed that
polymers also induce protein crystallization by competing with proteins for water and by
lowering the dielectric constant of the solution.

1.2.3 Other Parameters
Various other parameters are important in crystallizing a protein by gradually forcing the
protein to become less soluble. Protein solubility is sensitive and typically relies greatly on
parameters such as pH and temperature. 17 Most protein have been successfully been crystallized
at their respective physiological pH. It was once believed that proteins would be more readily
crystallized at their respective pI, however further research has proven that at physiological pH,
there is less risk of denaturation. Temperature dependence of protein solubility is due to the
protonation and deprotonation reaction constants of amino acid side chains.18 Protein
concentration is also a key parameter to allow for proper crystal nucleation. Common
concentration ranges from 5 to 30 mg/mL but can range to even lower and higher concentrations
depending on the solubility of the protein. Protein crystals will form and can form at various
concentrations but it has been identified that only at optimal concentrations will proteins
crystallize with reproducibility and consistency. The previously described parameters are only a
few of many parameters that can influence protein crystallization. However, as of today there are
still no clear definitive set of established parameters that can be associated as the key to
successful protein crystallization as crystallization parameters will differ from protein to protein.
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1.3

Cupin Family
The Cupin superfamily is a diverse family of proteins with a conserved 6 β-barrel domain

with a high diversity and range of biological functions as this family is associated with Archaea,
Eubacteria, and Eukarota.19 The identity of the Cupin family originated from identification and
recognition of a conserved motif found within proteins such as the wheat protein germin and
germin-like proteins (GLPS). Most proteins in this family shows low overall sequence
similarities however, they each contain two distinct short conserved cupin sequence motifs
Gx5HxHx3-6Ex6G (motif 1) and Gx5-7PxGx2Hx3N (motif 2), separated by a less conserved
intermotif region (15-50 residues). The patented “jelly roll” barrel is formed with the cupin
motif 1 and 2 along with the intermotif region where each forms two of the core six β-strands
found in the folded structure. These degree of high hydrophobic interactions and short loops
contribute to the thermal stability and protease resistant properties of proteins in this family.20
The Cupin superfamily consist of proteins with a wide range of biological functions
including enzymatic activities such as decarboxylases, dioxygenases, hydrolases, isomerases,
epimerases, and non-enzymatic functions such as seed storage or transcription factors.21 Studies
have shown that activity and function of cupins probably originated with ancestral cupins as
simple sugar and cyclic nucleotide non-enzymatic binding domains which eventually evolved to
metal-coordinating enzymatic domains. 22 This was based on the fact that a set of conserved
histidine residues can be traced back to the ancestral cupins. A majority of the metal-dependent
enzymes have been associated with metals such iron, nickel, zince, manganese, cobalt, or copper
as each cofactor allows for a unique chemistry. Well known enzymes in the cupin family such
oxalate oxidase and oxalate decarboxylase have been determined to be able to coordinate with a
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Mn ion. Other enzymes in this family like acireductone dioxygenase binds Ni and praline-3hyroxylase utilizes Fe as a cofactor. Purposed mechanisms of these enzymes generally involve
the sequential binding of the substrate and a dioxygen molecule to the metal cation. Initially
metal binding enzymes in this family were thought to possess ligands consisting of 3 His-1carboxylate. It is now however apparent that there are many variations in the sequence as
deletions or substitutions of the ligands can result in alternate binding sites. As of today, there
are many notable variations of these ligands in the binding site due to structural characterization
work. For instance, the ligands of various enzymes can consist of 2-His, 2-His-1-Gln, 3-His, 3His-1-Glu, etc. 23 Efforts toward elucidating the structure and role of these metal binding
enzymes has been beneficial for understanding the nature of metal binding enzymes and their
mechanistic properties in vivo.

1.3.1 Thiol Dioxygenase
Our interest in the Cupin family revolves around a sub group of enzymes in this family
called thiol dioxygenase. In the mammalian cell there are many processes that can result in the
oxidation of thiol groups due to the reactive free sulfhydryl groups to form disulfides, sulfinates,
sulfenates, and sulfonates. Many of these oxidations occur nonenzymatically yet, there are still a
number of thiol reactions that occur by enzymatic reactions. 24 It has been shown that there are
enzymes involved in these reactions which can oxidize free sulfhydryl groups with high degree
and specificity. One interesting group of enzymes that can oxidize free sulfhydryl groups
includes thiol dioxygenases cysteine dioxygenase (CDO) and cysteamine dioxgyenase (ADO).
To date, CDO and ADO are the only two reported mammalian thiol dioxygenases. CDO and
ADO are unique iron-dependent enzymes that adds molecular oxygen to sulfhydryl group to
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form a sulfinic acid in cysteine metabolism. These two thiol dioxygenases are essential for
hypotaurine/taurine biosynthesis.25 Cysteine and dioxygen are used as substrates by CDO to
form cysteinesulfinic acid which can then (1) decarboxylate to hypotaurine or (2) transaminate to
3-sulfinylpyruvate which can decomposes to pyruvate. ADO on the other hand uses the
substrate cysteamine, a decarboxylated cysteine derived during the coenzyme A synthesis
pathway. Once cysteamine is released during coenzyme A degradation, ADO converts
cysteamine and dioxygen to form hypotaurine which is further oxidized to taurine (Figure 1).
Thus, both CDO and ADO play key roles in thiol metabolism by regulating cysteine and
cysteamine levels in the body for the production of hypotaurine/taurine from two different
cysteine metabolites. Thiol metabolism for the production of hypotaurine/taurine has become of
importance because of the physiological relevance of taurine for cardiovascular function, the
retina, and the central nervous system.26
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Figure 1. Taurine biosynthesis pathway from cysteine. Image adapted from ref. 27.

1.3.1.1 CDO
Yamaguchi and coworkers were able to successfully purify and characterize CDO from rat
liver in the 1970s. They discovered that CDO had the capability to bind one atom of iron per
molecule and also went on to solve the amino acid sequence.28,29 Future contributions from other
groups went on to discover that the 200 amino acid residue protein was identical for rat and
murine CDOs while human CDO only differed by 16 amino acid residues.30 Influx of interest in
CDO started when clinical evidence indicated that malfunction in cysteine metabolism due to
CDO can lead to altered cysteine to sulfate ratio which causes sulfate depletion along with other
adverse effects.31,32 Other reports have shown that impaired cysteine catabolism was present in
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patients afflicted with rheumatoid arthritis, liver diseases, Parkinson disease, Alzheimer disease,
and systemic lupus erythematosus. Depletion of cysteine catabolism would either cause a
depletion of sulfate and taurine while leading to an accumulation of substrate cysteine which has
been speculated to impair sulfation reactions in vivo.33,34,35
O

-

+

NH3

O
O2
O

HS
O

+

O

NH3

S

-

O

-

Figure 2. Reaction catalyzed by CDO

The elucidation of the crystal structure of CDO from rat, mouse, and human has revealed
that it is indeed a member of the cupin family for it contained the patented cupin fold. CDO
contains a β-sandwhich of seven anti-parallel β-strands on the lower side (β1, β2, β4, β7, β9,
β12, and β13) and six anti-parallel β-strands (β3, β5, β6, β8, β10, β11) on the upper region.31,36,37
The cupin core is present in CDO as β-strands 3 and 4 corresponds to βC and βD (cupin motif 1),
β-strands 5 and 6 corresponds to βE and βF (intermotif region), and β-strands 7 and 8
corresponds to βG and βH (cupin motif 2). This illustration can be seen on Figure 3.
Another interesting discovery is that CDO contained a novel metal center with Fe as its
cofactor. Instead of a 3-His-1-Glu variation, it was revealed that CDO coordinated Fe2+ by a
facial triad of 3 histidine side chains without any carboxylate ligand present near the iron center.
It was evident that no other residue replaced the conserved glutamate as a metal-coordinating
ligand, thus indicating that CDO is a unique discovery as most monnuclear non-heme Fe2+
enzymes normally use the 2-His-1-Glu or 3-His-1-Glu coordination. Therefore, the tetrahedral
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coordination of mononuclear iron of CDO is unique for most cupin superfamily typically utilizes
a penta- or hexa- coordination metal center. Further work on CDO indicated that the novel
center of CDO would catalyze reactions differently than other classes of dioxygenases. Rather
than cleavage of a C-C bond or hydroxylation, CDO involves oxidation of a sulfyhydryl group.
Crystal structure of human CDO in complex with substrate L-cysteine36 along with crystal
structure of rate CDO with Fe2+ bound persulfenate intermediate suggest that Fe2+ directly
activates both cysteine and O2, causing a transfer of both oxygen atoms from the iron atom to a
single sulfur atom.31 This is possible because of the electron rich substrate compound. However,
studying of the mechanism of CDO has proved to be quite challenging because both the substrate
and resulting products are not detectable by UV-Vis absorption.
Crystal evidence from mammalian CDO also indicated that there is a unique crosslink in the
active site of the enzyme (Figure 3). A Cys-Tyr intramolecular crosslink between Cys93 and
Tyr157 is indicative of a rare thioether cofactor that has been identified to possibly play a role in
regulating CDO function via a substrate-regulation from cysteine to modulate the Cys-Tyr
cofactor formation as form of feed-forward activation.
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Figure 3. 1.5 Å Resolution Crystal Structure of Recombinant R. Norvegicus Cysteine
Dioxygenase illustrating the purin domain and a Cys-Tyr crosslink. Image taken from ref. 31.
(PDB 2B5H)

1.3.1.2 ADO
In 2007,studies were done on a hypothetical murine protein homolog of CDO encoded by
the gene Gm237 in the DUF1647 family which was identified to show significant cysteamine
dioxygenase activity in vitro.24 Sequence alignment of this murine protein homolog which was
named ADO when compared to CDO only resulted in 14%-19% similarity. However the
alignment indicated that ADO belongs to the cupin family while also potentially exhibiting the
same 3-His metal binding motif as CDO. Upon its first discovery from horse kidney in 1963,
ADO has been reported to require sulfide, elemental sulfur, selenium, or hydroxylamine to
function.38 The recombinant ADO however, reported that the use of ferrous iron as a cofactor
was necessary while requiring none of the exogenous elements mentioned previously. To date,
little information about ADO is known. For several decades, a vast majority of the research
effort was focused more on CDO because of CDO and its association as a major regulator of
taurine synthesis. However, association of cysteamine as a potential intermediate in taurine
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biosynthesis for the cause of Hallervorden-Spatz syndrome has renewed interest. Lack of
panthothenate kinase (PANK2) which is necessary for the synthesis of coenzyme A and release
of cysteamine during coenzyme A degradation has been identified to be a cause of HallervordenSpatz syndrome. 39 Furthermore, evidence also indicates that cysteamine could serve as an
endogenous regulator of the immune system activity 40,41 and a potential therapeutic agent of
Huntington disease. 42,43
ADO like many other cupins possess the two conserved cupin motifs, however like CDO,
it is missing the highly conserved glutamate in motif 1 as this residue is replaced by valine or
glycine (compared to cysteine or glycine in CDO). Motif 2 for the cupin family is less conserved
among the DUF1637 family but all contain the third metal-binding histidine residue (His 193 in
human ADO). The alignment would suggest that this third histidine residue would be involved
in iron ligand binding, however no direct evidence have suggested that. Even though both CDO
and ADO utilizes a thiol substrate to catalyze a similar reaction, it has been reported that ADO
could potentially contain an iron binding site that is different from CDO due to ADO’s ability to
retain bound iron while iron can dissociate rather easily from CDO.24,31
For these reasons, it is necessary to pursue higher levels of understanding of ADO. ADO
is non-heme mononuclear iron dependent enzyme that catalyzes the oxidation of cysteamine to
hypotaruine in the presence of oxygen. Sequence alignment of various ADO strands indicates
that ADO consist of multiple intriguing conserved and missing residues as shown by Figure 5.

19

Figure 4. Sequence alignment of various strands of ADO.
Compasrison of hADO (1) with various strands of ADO. Thee conserved glutamate is replaced by ether glycine or
valine for ADO. A potential cys-tyr crosslink similar to CDO can be also be seen. Note: black highlights are from conserved
residues similar to the cupin family and lighter highlights are for conserved residues within ADOs.27

To date, no structure of ADO has been reported. The structure of an enzyme is a crucial factor
for indebt mechanistic study and understanding the regulation roles of the enzyme in vivo. For
these reasons, we are highly interested in trying to pursue the structure of ADO.
+
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-

Figure 5. Reaction catalyzed by ADO

2
2.1

MATERIALS/METHODS

hADO Purification
The gene human ADO (hADO) was purchased from DNASU and was cloned to pET28

plasmid with a His-tag and transferred into B L21 (DE3) competent cells. The E-coli cells with
hADO were grown in Luria Broth at 37oC with shaking at 200 rpm at first in 10 mL and then
transferred to 50 mL medium size containing 10 mg/mL and 50 mg/mL kanamycin respective to
the increasing Luria Broth size. hADO cells from the medium scale was then transferred to a
500 mL size Luria Broth with 100 mg/mL kanamycin. The large scale culture was grown at
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37oC with shaking at 200 rpm until O.D. was approximately 0.6. At this point, the temperature
was decreased to 25oC and induced with 0.6mM isopropyl-β-thiogalactopyranoside and allowed
to grow overnight. The cells were then harvested by centrifugation at 4oC, 8000 x g for 20 min.
Cell pellets were obtained and dissolved in a lysis buffer (20 mM Tris pH 8.5, 300 mM NaCl,
5% glycerol) and the re-suspended mixture was disrupted using a cell disruptor. The cell debris
was centrifuged at 4oC and 27000 x g for 1 hour. The supernant was obtained and subjected to
an affinity column (Ni-NTA resin, 26 x 200 mm) and eluted at a flow rate of 4 mL/min by using
a linear imidazole gradient generated from buffer A (20 mM Tris-base, pH 8.0, 300 mM NaCl,
5mM imidazole, 5% glycerol) and 0-80% of buffer B (20 mM Tris-base, pH 8.0, 300 mM NaCl,
500 mM imidazole, 5 % glycerol). The hADO fraction was then concentrated and loaded onto a
size exclusion column HiLoad Superdex 200 and eluted at a flow rate of 2 mL/min with a
desalting buffer (10 mM Tris-base, pH 8.0, 5% glycerol). 12% SDS-PAGE was used to monitor
and confirm that the peak had a consisted weight to that of the theoretical molecular weight of
hADO mono (MW= 29 KDa).
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Figure 6. Plasmid map of ADO.
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Figure 7. FPLC elution profile from Ni-NTA column and Superdex 75 on hADO.
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SDS-PAGE w/ 1mM DTT

P1

P2

P3

68 kDa

Figure 8. SDS-PAGE of hADO w/o DTT and with DTT after Superdex 75.

Figure 9. SDS-PAGE of hADO before and after treatment with 3mM substrate. A and B
corresponds to hADO before treatment with substrate and A1 and B1 is after treatment with
substrate.
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2.2

hADO Crystallization Parameters
Crystals were observed for hADO protein prepared by two different methods.

2.2.1 As Isolated hADO without His-tag
hADO purified from HiLoad Superdex 75 was incubated with TEV protease (1:10 ratio)
with stirring overnight at 4oC. The TEV treated hADO was then subjected to a 5 mL Ni-NTA
resin and eluted at a flow rate of 1.5 mL with a linear imidazole gradient generated from buffer
A and buffer B. The hADO fraction was concentrated and loaded onto a desalting column and
eluted with the desalting buffer without any glycerol.
2.2.2 hADO without His-tag reconstituted with Fe
hADO without His6-tag were incubated with 20mM EDTA while stirring overnight at
4oC. The EDTA-treated hADO was then loaded onto a desalting column and eluted with the
desalting buffer to remove any EDTA. The collected EDTA treated protein was then made
anaerobic via a shrink line under constant N2 gas. In an anaerobic glove box, iron ammonium
sulfate was dissolved in anaerobic water and added to the anaerobically prepared hADO. The
Fe-reconstituted hADO was then subjected to another desalting via a desalting column with
desalting buffer without glycerol.
2.3

Screening by Hampton Crystal Kits
hADO prepared as previously mentioned were screened by approximately 100 different

conditions each experiment using Hampton research crystal screen kits at varying protein
concentrations (10 mg/mL, 15 mg/mL, 20 mg/mL, 25 mg/mL, 30 mg/mL). Fresh DTT or
cysteamine substrate was prepared and 1mM or 10 mM of substrate were added to each protein
concentration prior to screening. 1 uL of each protein concentration was mixed with 1 uL of
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mother liquor via a Crystal Screen Robot via micro-batch diffusion method and stored and
monitored at 16°C until crystals were observed and harvested.
The hADO crystals were harvested from the drops and flash frozen with liquid nitrogen
and sent to SER-CAT for remote analysis. The diffraction data were collected at SER-CAT
beam ID-22 or BM-22 line with 180 frames.
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3

RESULTS

Evidence of potential crystals was observed at multiple conditions. Screening with Fereconstituted hADO yielded in unstable and un-harvestable seed shaped crystals at various
conditions. The crystals from Figure 8 were the result of 15mg/mL hADO protein, 0.2M
ammonium acetate, 0.1M Hepes pH 7.5, 45%v/v-2-methyl-2,4, pentanediol where 1 mM
substrate was added to hADO resulting in A and 10 mM substrate for the crystal formed in
B.

A

B

Figure 10. Seed-like hADO crystals were observed from the same condition at two
different substrate concentration.

Crystals from C in Figure 9 resulted from 20 mg/mL of hADO, 10 mM substrate, 0.2M
potassium tartrate tetrahydrate, 0.1M sodium citrate tribasic dehydrate pH 5.6, 2.0 M
ammonium sulfate. Crystal D was the result of 15 mg/mL hADO protein, 10mM substrate,
0.2M lithium sulfate monohydrate, 0.1M Bis-Tris pH 5.5, and 25% w/v PEG 3350.
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C

D

Figure 11. Seed-like hADO crystals observed with Fe-reconstituted hADO.

A different hADO crystal structure was observed at 15 mg/mL (E) and 20 mg/mL hADO
(F), 0.2 Sodium fluoride, 20% w/v PEG 3350 from Fe-reconstituted hADO shown on Figure
10. The crystals were collected stable and robust enough to be collected.

E

F

Figure 12. Flower-like hADO crystals observed with Fe-reconstituted hado.
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hADO crystals without Fe reconstitution yielded in a long rod crystal rod at the condition of
20 mg/mL hADO, 0.1 M Sodium cacoldylate trihydrate pH 6.5, 0.1 M Sodium acetate
trihydrate (Figure 11).

Figure 13. Rod-shaped hADO crystals
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Figure 14. SER-CAT beam analysis of hADO crystals from Figure 9.

Figure 15. SER-CAT beam analysis of hADO crystals from Figure 9.
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Figure 16. SER-CAT imaging analysis of the rod-shaped hADO.

4

DISCUSSION

ADO is non-heme mononuclear iron dependent enzyme that catalyzes the oxidation of
cysteamine to hypotaruine in the presence of oxygen. To date, no structure of ADO has
been reported. Blasts study indicates that CDO is the closest relative of ADO but only with
approximately 19% sequence similarity. Findings from the structure of CDO indicate that
CDO utilizes a 3-His metal binding motif. Sequence study also indicates that ADO also has
this conserved 3-His metal binding motif. The structure of an enzyme is a crucial factor for
indebt mechanistic study and understanding the regulation roles of the enzyme in vivo.
Recombinant hADO cloned to pET28 plasmid with a His-tag was successfully
cloned and purified as previously mentioned above. The purification conditions allowed for
optimal purification of the protein normally yielding on average of 1-3 mg/mL. Ni-NTA
purification of hADO showed an elution profile with normally one distinctive peak (Figure
5). SDS-PAGE of the protein after Ni-NTA shows two distinctive major bands
approximately at 29 KDa and 58 KDa. Further purification of hADO with Superdex 75 will
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result in typically 3 peaks (Figure 5). Peak 1does not show absorbance at 280 nm and does
not show any bands when analyzed by SDS-PAGE, thus indicating that it is not the desired
protein hADO. It does absorb strongly at 260 nm, suggesting that it could be from DNA.
Peak 2 and peak 3 both show strong protein absorbance at 280nm and SDS-PAGE further
validated the expected two bands of hADO (Figure 6). The protein proved to be rather
stable, making it optimal to handle the protein without constant freezing of protein as long
as the protein was kept under ice.
Crystallization screenings of hADO yielded in various potential conditions from the
tested parameters. Initial screenings of hADO with His-tag intact resulted in lack of protein
crystal formation. His-tag removal via TEV protease helped increase potential crystal
formation for the protein. It has previously been reported for CDO and other proteins that
His-tag removal may help in stabilizing the protein. The flexible tail end from His-tag may
disrupt proper protein nucleation. However, this is not true for all scenarios as it has been
shown that some proteins are easier and able to be crystallize with the his-tagg still intact.
When removed and purified from bacterial cell, hADO tends to for a mixture of monomer
and dimer as indicated from SDS-PAGE. When DTT is added to the loading buffer gel, the
normally seen two bands converge into just one single band (Figure 6). This suggests that
the ADO eluted from the size exclusion column are in different multimer forms. This
resulted in initially screenings with DTT as a reducing agent for hADO at various
concentrations in order to keep hADO in a monomeric form. Crystal formation was
observed after these modifications, however the crystals observed did not have a definitive
shape and were highly unstable during crystal harvest. One key finding was that the
substrate cysteamine was able to reduce hADO to a monomer in the same manner that DTT
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can as indicated via SDS-PAGE (Figure 7). It has been shown previously that substrate can
help to stabilize and support protein during crystallization11,13. This finding facilitated the
usage of the substrate cysteamine as a substitute for DTT as a reducing agent.
CDO has been previously reported to incorporate various divalent metals as a cofactor as
Mccoy and Stipanuk’s was able to crystallize CDO with nickel and iron respectively.
Based on this notion, crystallization of hADO was explored with different metals. No
results were obtained from crystallization of hADO with nickel however, hADO with Fereconstituted did result in formation of low diffracting crystals. Even though Fe has been
noted to be the preferred metal for catalysis, it has been proven by various groups that the
native metal is not always the desired metal needed for crystallization conditions. Test
revolving around as purified hADO without metal reconstitution or EDTA treatment yielded
in a crystal structure of a rod, very different from hADO reconstituted with Fe. hADO
grown in Luria broth will be incorporated with various metals ranging due to trace amounts
of metals present in the Luria broth. Thus, the identity of the metal resulting in the
formation of the rod crystal is unknown. The rod crystal collected also resulted in slightly
diffracting crystals but proved to be promising as it has been noted by Stipanuk that
crystallization of hCDO also resulted in rod-shaped crystals.

1

CONCLUSION

These results have helped to reveal crucial conditions needed for the structure elucidation
of hADO. From the nature of the crystal formation and diffraction patterns of the analyzed
crystals, it is evident that the crystals obtained are not from salt formation. The results for
hADO prove to be promising with various parameters needing to be refined in order to solve
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the structure. For future work, the range of protein concentration of hADO should be
explored in higher concentrations as the protein has shown promise to crystallize in
concentration ranges from 15-25 mg/mL. More emphasis could also be focused on the
metal cofactor which seems to play a role in the types of hADO crystals formed. Apo
protein along with other divalent metals other than Fe can be explored as crystallization
parameters. The role of the substrate cysteamine as a natural reducing agent has proven to
be a crucial factor for crystal stability for harvesting; however various other reducing agents
such as previously tested DTT should be revisited and tested at various concentrations.
Once the optimal conditions for hADO crystals are determined, then procedures for phasing
for a de novo structure needs to be implemented. This could be through various methods
such as heavy metal soaking by incubating the protein crystals with metals such as Pt, Au,
etc for a short time. Another approach is growing the protein with M9 media that is
substituted with Set-Met.
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